Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Update of variants identified in the pancreatic β‐cell K ATP channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes

Elisa De Franco, Cécile Saint‐Martin, Klaus Brusgaard and 17 more

Human Mutation · 2020 · Review · CC BY

doi:10.1002/humu.23995

Abstract

The most common genetic cause of neonatal diabetes and hyperinsulinism is pathogenic variants in ABCC8 and KCNJ11. These genes encode the subunits of the β-cell ATP-sensitive potassium channel, a key component of the glucose-stimulated insulin secretion pathway. Mutations in the two genes cause dysregulated insulin secretion; inactivating mutations cause an oversecretion of insulin, leading to congenital hyperinsulinism, whereas activating mutations cause the opposing phenotype, diabetes. This review focuses on variants identified in ABCC8 and KCNJ11, the phenotypic spectrum and the treatment implications for individuals with pathogenic variants.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

ATP‐sensitive potassium (KATP) channels were found to couple glucose metabolism to membrane electrical activity and insulin release over 30 years ago (Ashcroft, Harrison, & Ashcroft, 1984; Cook & Hales, 1984; Rorsman & Trube, 1985). This landmark discovery was fundamental to further understanding of the insulin secretion pathway whereby glucose metabolism results in a change in ratio of ADP and ATP. The binding of ATP to the channel induces channel closure, depolarization of the membrane, and activation of voltage‐dependent calcium channels, leading to calcium influx, and insulin granule exocytosis (Figure 1a).

Given the role of the KATP channel in insulin secretion, it is not unexpected that variants in KCNJ11, encoding the four pore‐forming inwardly rectifying Kir6.2 subunits, and ABCC8, encoding the four sulphonylurea receptor 1 (SUR1) subunits of the channel, can cause hypo‐ or hyperglycemia (Babenko et al., 2006; Gloyn, Pearson, et al., 2004; Thomas et al., 1995; Thomas, Ye, & Lightner, 1996). Identifying these mutations is important for informing prognosis, medical management, and recurrence risk.

Over recent years, the number of variants identified in these two genes has expanded tremendously. In 2006, 124 disease‐causing mutations were reported, which increased to 265 pathogenic variants 3 years later (Flanagan et al., 2009; Gloyn, Siddiqui, & Ellard, 2006). By combining published reports together with data from five international molecular genetic screening laboratories in the UK, Denmark, France, and the United States of America, we now report 953 pathogenic ABCC8 and KCNJ11 variants (Tables S1–S6) and discuss the role of these genes in congenital hyperinsulinism (CHI) and monogenic diabetes.

CONGENITAL HYPERINSULINISM

CHI is characterized by the inappropriate secretion of insulin despite low blood glucose, which can result in irreversible brain damage if not promptly treated (Helleskov et al., 2017). The condition has a variable phenotype usually presenting during the neonatal period or infancy with seizures and/or coma and a large birth weight due to high levels of insulin acting as a growth factor in utero.

Although most cases of CHI are sporadic, rare familial forms have been well documented. Sporadic CHI has an estimated incidence of between 1 in 27,000 and 1 in 50,000 live births (Glaser, Thornton, Otonkoski, & Junien, 2000; Otonkoski et al., 1999). However, in some isolated populations or in countries with high rates of consanguineous unions, the incidence is higher (i.e., 1 in 2,675 to 1 in 3,200; Mathew et al., 1988; Otonkoski et al., 1999).

CHI due to KATP channel mutations

Loss‐of‐function ABCC8 mutations were first described in 1995 (Thomas et al., 1995). These mutations either prevent trafficking of the channel to the membrane surface or are associated with channels that reach the surface but are not fully responsive to MgADP activation (Figure 1; Ashcroft, 2005; Nichols et al., 1996; Taschenberger et al., 2002). The majority of ABCC8 loss‐of‐function mutations are recessively acting with a small number of dominant missense mutations reported that produce channels that traffic to the membrane but have impaired mgADP activation.

Fewer loss‐of‐function mutations have been reported in KCNJ11 in keeping with the gene being much smaller (1173 vs. 4749 bases, respectively; Thomas et al., 1996). Similar to ABCC8, both dominant and recessively acting KCNJ11 mutations have been described (Pinney et al., 2013). Mutations in these two genes together account for 36–70% of CHI cases (Kapoor et al., 2013; Snider et al., 2013).

There exist mouse models for KATP channel CHI; however, their inability to fully recapitulate the human phenotype means that they have a limited value for studying specific disease mechanisms. For example, mice generated with a deletion of ABCC8 or KCNJ11, or the homozygous recessive KCNJ11 mutation p.(Tyr12Ter), do not have the sustained neonatal hypoglycemia observed in humans with homozygous null mutations. Instead the blood glucose levels normalize in the mouse within a few days of birth with glucose intolerance developing in later life (Hugill, Shimomura, Ashcroft, & Cox, 2010; Miki et al., 1998; Seghers, Nakazaki, DeMayo, Aguilar‐Bryan, & Bryan, 2000). The differences in the phenotype between mice and humans are not fully understood, but they highlight the need to develop human‐specific models for studying disease mechanisms.

Clinical management of KATP channel CHI

In 2015, the Pediatric Endocrine Society published recommendations for the evaluation and management of persistent hypoglycemia in neonates, infants, and children (Thornton et al., 2015). The main treatment for CHI is the KATP channel‐opener diazoxide; however, patients with ABCC8/KCNJ11 mutations that prevent trafficking to the membrane do not respond to the drug as diazoxide targets the SUR1 subunit of the KATP channel. For approximately 50% of patients with mutations that do not prevent the channel from reaching the membrane, diazoxide is an effective treatment (Boodhansingh et al., 2019). For patients with diazoxide‐unresponsive CHI, second‐line treatment with somatostatin analogs may be helpful to control hypoglycemia; however, adverse effects on somatostatin analogs, and likewise diazoxide, have been reported (Demirbilek et al., 2014; Herrera et al., 2018).

The mode of inheritance of the KATP channel mutation determines the pancreatic histological subtype (de Lonlay et al., 1997; de Lonlay et al., 2002; Jack, Walker, Thomsett, Cotterill, & Bell, 2000; Rahier et al., 1984). Inheritance of two recessively acting or one dominant ABCC8/KCNJ11 mutation results in diffuse disease affecting the entire pancreas. Focal disease is caused by somatic loss of the maternal chromosome 11p15.5 region by uniparental disomy that unmasks a paternally inherited KATP channel mutation at 11p15.1. These focal lesions often appear histologically as small regions of islet adenomatosis that develop as a result of the imbalanced expression of maternally imprinted tumor suppressor genes H19 and p57Kip2, and the increased expression of the paternally derived insulin‐like growth factor II gene (Craigie et al., 2018; Damaj et al., 2008; de Lonlay et al., 1997). Rarely, giant focal lesions have been described where virtually the whole of the pancreas is affected (Ismail et al., 2012). Atypical mosaic disease has also been reported in a small number of cases (Han et al., 2017; Houghton et al., 2019; Hussain et al., 2008; Sempoux et al., 2011).

The identification of a single recessively acting KATP channel mutation in an individual with CHI predicts focal disease with 84–97% sensitivity, with a positive predictive value up to 94% (Mohnike et al., 2014; Snider et al., 2013). 18F‐DOPA PET/CT scanning can identify and localize a focal lesion before surgery (Otonkoski et al., 2006). Intraoperative ultrasound may further aid the surgeon to perform tissue‐sparing pancreatic resection in focal CHI, which is potentially curative (Bendix et al., 2018).

DIABETES MELLITUS

Diabetes is the opposing disorder to CHI and results from hyper‐ rather than hypoglycemia. Current estimates suggest that approximately 0.4% of all diabetes (and up to 3.5% of those diagnosed under 30 years of age) has a monogenic cause (Shepherd et al., 2016; Shields et al., 2017). Individuals diagnosed with monogenic diabetes outside of infancy are generally classified as having maturity onset diabetes of the young, whereas neonatal diabetes (NDM) describes congenital diabetes. In individuals with NDM, impaired insulin secretion results in a low birth weight and hyperglycemia diagnosed before the age of 6 months (Hattersley & Ashcroft, 2005). The minimal incidence of NDM has been calculated to be between 1 in 89,000 and 1 in 160,949 live births (Grulich‐Henn et al., 2010; Wiedemann et al., 2010).

Later‐onset diabetes due to KATP channel mutations

Dominantly acting mutations in the KATP channel genes have been rarely described in individuals with later‐onset diabetes in the absence of documented hyper‐ or hypoglycemia in the neonatal period (Bowman et al., 2012; Hartemann‐Heurtier et al., 2009; Huopio et al., 2003; Koufakis et al., 2019; Tarasov et al., 2008). The mechanism(s) leading to this variable penetrance are not fully understood and may differ according to whether the mutation is causing a gain or loss of channel function. Interestingly, in one study, the generation of a mouse model harboring a homozygous dominantly acting loss‐of‐function ABCC8 mutation p.(Glu1507Lys) recapitulated the biphasic phenotype with the mice having increased insulin secretion in early life and reduced insulin secretion later on. This was shown to be resulting from a reduction in insulin content rather than a reduction of islet number and/or size. Heterozygosity for the mutation did, however, not result in a phenotype in the mouse, further highlighting differences between the mouse models and human disease (Shimomura et al., 2013).

Neonatal diabetes due to KATP channel mutations

Strong support for the role of gain‐of‐function KATP channel mutations in the etiology of diabetes came from the observation that mice overexpressing a mutant KATP channel with reduced ATP sensitivity developed diabetes within 2 days (Koster, Marshall, Ensor, Corbett, & Nichols, 2000). In 2004, the first heterozygous activating KCNJ11 mutations causing NDM were described in humans with activating ABCC8 mutations reported 2 years later (Babenko et al., 2006; Gloyn, Pearson, et al., 2004; Proks et al., 2006). Mutations in these two genes together have now been shown to account for approximately 40% of NDM cases (De Franco et al., 2015; Stoy et al., 2008).

Both dominant and recessive activating mutations are frequently identified in ABCC8. Conversely for KCNJ11, all, but one of the mutations reported so far, p.(Gly324Arg), have been dominantly acting. The majority (~60%) of dominant mutations arise “de novo,” so there is often no family history of diabetes; however, germline mosaicism has been observed in some families (Edghill et al., 2007; Gloyn, Cummings, et al., 2004).

There is added complexity associated with ABCC8 mutations, as compound heterozygosity for both an activating and an inactivating mutation can cause diabetes (Ellard et al., 2007). Furthermore, a recessively inherited ABCC8 nonsense variant has been reported in two cases with NDM, which leads to the deletion of the in‐frame exon 17 likely resulting in enhanced sensitivity of the channel to intracellular MgADP/ATP (Flanagan et al., 2017).

The specific KATP channel mutation identified determines whether the diabetes will cause permanent or transient NDM (Gloyn, Reimann, et al., 2005; Patch, Flanagan, Boustred, Hattersley, & Ellard, 2007). Variable penetrance within families with mutations leading to transient diabetes is observed with some individuals being diagnosed with diabetes at birth, yet others developing diabetes for the first time in adulthood (see previous section on adult‐onset diabetes; Flanagan, Edghill, Gloyn, Ellard, & Hattersley, 2006).

Spectrum of central nervous system features in KATP channel NDM

Central nervous system (CNS) features are frequently reported in individuals with KATP channel NDM due to the Kir6.2 and SUR1 proteins being expressed in the brain (Karschin, Ecke, Ashcroft, & Karschin, 1997; Liss, Bruns, & Roeper, 1999; Sakura, Ammala, Smith, Gribble, & Ashcroft, 1995; Schmahmann & Sherman, 1998). The most severe neurological phenotype is termed as developmental delay, epilepsy and neonatal diabetes (DEND) syndrome, which includes muscle weakness and hypotonia (Hattersley & Ashcroft, 2005). Intermediate DEND (iDEND) syndrome is diagnosed when epilepsy is absent or presents after the age of 12 months (Gloyn, Diatloff, et al. 2006). Clinical studies have reported CNS features in approximately 20–30% of individuals with KATP channel permanent NDM (De Franco et al., 2015; Massa et al., 2005; Sagen et al., 2004).

Since these initial reports, studies on larger cohorts of individuals affected with KATP channel NDM have characterized the neurological features in more detail. Additional features reported include autism and attention deficit hyperactivity disorder (ADHD), anxiety and sleep disorders, dyspraxia, and learning difficulties, resulting in impaired attention, memory, visuospatial abilities, and executive function (Beltrand et al., 2015; Bowman et al., 2016; Bowman et al., 2017; Bowman, Day, et al., 2018; Busiah et al., 2013; Landmeier, Lanning, Carmody, Greeley, & Msall, 2017). More important, it is now recognized that some degree of impairment can be detected on neuropsychological testing in the majority of patients with KATP channel mutations, even if there is no obvious CNS involvement (Busiah et al., 2013; Carmody et al., 2016).

Clinical management of neonatal diabetes and CNS features due to KATP channel mutations

The identification of a KATP channel mutation can have an impact on the medical management of patients with NDM as approximately 90% can transfer from insulin injections to high‐dose sulphonylurea tablets (Pearson et al., 2006; Zung, Glaser, Nimri, & Zadik, 2004). Sulphonylureas bind to the SUR1 subunit of the KATP channel and close it independently of ATP, resulting in excellent long‐term glycemic control and improved quality of life for affected patients and their families (Babenko et al., 2006; Bowman, Sulen et al., 2018; Rafiq et al., 2008). Patients who are unable to transfer to sulphonylureas tend to have a longer duration of diabetes before attempting transfer or functionally severe mutations (Babiker et al., 2016; Thurber et al., 2015). Few side effects and no episodes of severe hypoglycemia involving seizures or loss of consciousness have been reported in individuals with sulphonylurea‐treated neonatal diabetes (Bowman, Sulen, et al., 2018; Codner, Flanagan, Ellard, Garcia, & Hattersley, 2005; Kumaraguru et al., 2009; Lanning et al., 2018).

Sulphonylureas can improve the neurological features in people with KATP channel NDM, particularly in the first year of treatment (Beltrand et al., 2015; Fendler et al., 2013; Stoy et al., 2008). However, these features do not fully resolve after sulphonylurea therapy and persist for a long term into adulthood (Bowman, Day et al., 2018; Bowmen, Sulen, et al., 2018). Higher doses of sulphonylureas are recommended for patients with severe neurological features in an attempt to mitigate this (https://www.diabetesgenes.org/). In addition, starting sulphonylurea therapy as early as possible after a genetic diagnosis is crucial as the largest improvements appear to occur in younger patients (Beltrand et al., 2015; Shah, Spruyt, Kragie, Greeley, & Msall, 2012).

GENETIC VARIATION IN ABCC8 AND KCNJ11

KCNJ11 (MIM# 600937) is located 4.5Kb from ABCC8 on chromosome 11p15.1 and has a single exon encoding for the 390‐amino acid Kir6.2 protein (GenBank NM_000525.3). ABCC8 consists of 39 exons that encode for the 1,582 amino acids of SUR1 (NM_001287174.1; MIM# 600509). This gene has an alternatively spliced recognition site at the 5′ end of exon 17, which results in two different transcripts differing in length by a single amino acid (GenBank AH003589.2). This alternative splicing has led to discrepancies in the literature for nomenclature of variants present in 17–39, which differ by a single amino acid depending on the isoform used (1581 amino acids, NM_000249.3 and 1582 amino acids, NM_001287174.1). For the purpose of this review, we have described ABCC8 variants according to the longer isoform (NM_001287174.1).

Disease‐causing variants

A total of 748 ABCC8 and 205 KCNJ11 pathogenic or likely pathogenic variants have been identified in individuals with CHI or NDM (Table 1 and Table 3 and Tables S1 and S4) — please note that these tables are meant to direct to the appropriate references and laboratories. They do not provide in‐depth clinical information and variants that had been previously reported as pathogenic with a GnomAD frequency compatible with the disease frequency (as calculated by http://cardiodb.org/allelefrequencyapp/ using a biallelic mode of inheritance, a prevalence of 1/50,000, an allelic heterogeneity of 0.1, genetic heterogeneity of 0.5, and penetrance of 0.5) were not re‐assessed.

Founder mutations have been identified in many populations with the best recognized example being the ABCC8 p.(Phe1388del) and c.3992‐9G>A mutations present in >90% of cases from the Ashkenazi Jewish population (Nestorowicz et al., 1996; Otonkoski et al., 1999). In the Irish population, a deep intronic ABCC8 founder mutation at position c.1333‐1013G>A has been described that generates a cryptic splice site and causes pseudoexon activation (Flanagan et al., 2013). Founder mutations have also been reported in Hispanic (Aguilar‐Bryan & Bryan, 1999), Bedouin (Tornovsky et al., 2004), Spanish (Fernandez‐Marmiesse et al., 2006), Finnish (Otonkoski et al., 1999), and Turkish populations (Flanagan et al., 2013).

Common variation in ABCC8 and KCNJ11

Three hundred and sixty‐eight benign/likely benign variants and variants of uncertain significance have been observed in both genes (Tables 2, 3, 4, S2, S3, S5, and S6). Two common variants in linkage disequilibrium, p.(Glu23Lys) in KCNJ11 and p.(Ser1370Ala) in ABCC8, predispose to type 2 diabetes (Florez et al., 2004). Although their effect size is small (odds ratio ~1.2), given that 58% of the population carry at least one lysine allele at residue 23 in KCNJ11, this equates to a sizeable population risk (Gloyn, Weedon, et al., 2003; Nielsen et al., 2003).

Variant interpretation

Given the highly polymorphic nature of ABCC8 and KCNJ11, the occurrence of both activating and inactivating mutations, the multiple modes of inheritance of disease, and the variable penetrance associated with dominantly acting mutations, interpreting variants identified in these genes can be extremely challenging. Although the identification of a null ABCC8 or KCNJ11 variant(s) in an individual with CHI provides strong evidence for pathogenicity, finding a missense variant is insufficient to assign disease causality and, as such, additional support is required to achieve a “pathogenic” classification according to the guidelines set out by the American College of Medical Genetics (Richards et al., 2015).

Large variant databases such as GnomAD and LOVD are powerful tools that aid in variant interpretation and allow for reclassification of variants (Fokkema et al., 2011; Lek et al., 2016). As such, some variants previously reported as pathogenic in the literature have now been found to be too common to be causative of disease and have now be reassigned as a variant of uncertain significance or a benign variant (Tables S2, S3, S5, and S6).

FUTURE PROSPECTS

Although sulphonylureas provide a safe and effective treatment for the majority of individuals with KATP channel NDM, for patients with CHI, pharmacological management of the condition is not always successful. Current efforts are, therefore, focusing on the development of new pharmacological treatments for this condition (Banerjee, De Leon, & Dunne, 2017; De Leon et al., 2008; Ng, Tang, Seeholzer, Zou, & De Leon, 2018; Patel et al., 2018; Powell et al., 2011; Senniappan et al., 2014).

Progress is also being made in terms of genetic screening, with a recent report describing the use of noninvasive prenatal testing of a paternally inherited KCNJ11 activating mutation in cell‐free fetal DNA (De Franco et al., 2017). Implementation of noninvasive prenatal testing for maternally inherited mutations will be extremely important, as a previous study suggested that sulphonylurea can cross the placenta and influence fetal growth with implications for treatment of monogenic diabetes pregnancies (Myngheer et al., 2014; Shepherd, Brook, Chakera, & Hattersley, 2017).

SUMMARY

The discovery of both inactivating and activating KATP channel mutations has firmly established the critical role of the channel in insulin secretion. The highly polymorphic nature of the two genes along with the occurrence of both gain‐of‐function and loss‐of‐function mutations as well as multiple different modes of inheritance can make variant interpretation extremely challenging. Rapid testing is absolutely crucial for all patients with CHI or NDM because finding a mutation has a huge impact on the clinical management of these conditions.

References 107

  1. 1.

    Aguilar‐Bryan, L., & Bryan, J. (1999 ). Molecular biology of adenosine triphosphate‐sensitive potassium channels. Endocrine Reviews, 20(2), 101–135.

    Not in our library10.1210/edrv.20.2.0361

  2. 2.

    Ashcroft, F. M. (2005 ). ATP‐sensitive potassium channelopathies: Focus on insulin secretion. Journal of Clinical Investigation, 115(8), 2047–2058.

    Not in our library10.1172/jci25495

  3. 3.

    Ashcroft, F. M., Harrison, D. E., & Ashcroft, S. J. (1984 ). Glucose induces closure of single potassium channels in isolated rat pancreatic beta‐cells. Nature, 312(5993), 446–448.

    Not in our library10.1038/312446a0

  4. 4.

    Babenko, A. P., Polak, M., Cave, H., Busiah, K., Czernichow, P., Scharfmann, R., … Froguel, P. (2006 ). Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. New England Journal of Medicine, 355(5), 456–466.

    Not in our library10.1056/nejmoa055068

  5. 5.

    Babiker, T., Vedovato, N., Patel, K., Thomas, N., Finn, R., Männikkö, R., … Hattersley, A. T. (2016 ). Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes. Diabetologia, 59(6), 1162–1166.

    Not in our library10.1007/s00125-016-3921-8

  6. 6.

    Banerjee, I., De Leon, D., & Dunne, M. J. (2017 ). Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient. Orphanet Journal of Rare Diseases, 12(1), 70.

    Not in our library10.1186/s13023-017-0621-5

  7. 7.

    Beltrand, J., Elie, C., Busiah, K., Fournier, E., Boddaert, N., Bahi‐Buisson, N., … Polak, M. (2015 ). Sulfonylurea Therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations. Diabetes Care, 38(11), 2033–2041.

    Not in our library10.2337/dc15-0837

  8. 8.

    Bendix, J., Laursen, M. G., Mortensen, M. B., Melikian, M., Globa, E., Detlefsen, S., … Christesen, H. T. (2018 ). Intraoperative ultrasound: A tool to support tissue‐sparing curative pancreatic resection in focal congenital hyperinsulinism. Frontiers in Endocrinology (Lausanne), 9, 478.

    Not in our library10.3389/fendo.2018.00478

  9. 9.

    Boodhansingh, K. E., Kandasamy, B., Mitteer, L., Givler, S., De Leon, D. D., Shyng, S. L., … Stanley, C. A. (2019 ). Novel dominant KATP channel mutations in infants with congenital hyperinsulinism: Validation by in vitro expression studies and in vivo carrier phenotyping. American Journal of Medical Genetics. Part A, 179, 2214–2227.

    Not in our library10.1002/ajmg.a.61335

  10. 10.

    Bowman, P., Broadbridge, E., Knight, B. A., Pettit, L., Flanagan, S. E., Reville, M., … Hattersley, A. T. (2016 ). Psychiatric morbidity in children with KCNJ11 neonatal diabetes. Diabetic Medicine, 33(10), 1387–1391.

    Not in our library10.1111/dme.13135

  11. 11.

    Bowman, P, Day, J, Torrens, L, Shepherd, MH, Knight, BA, Ford, TJ, … Zeman, A. (2018 ). Cognitive, neurological, and behavioral features in adults with KCNJ11 neonatal diabetes. Diabetes Care, 42(2), 215–224.

    Not in our library10.2337/dc18-1060

  12. 12.

    Bowman, P., Flanagan, S. E., Edghill, E. L., Damhuis, A., Shepherd, M. H., Paisey, R., … Ellard, S. (2012 ). Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia, 55(1), 123–127.

    Not in our library10.1007/s00125-011-2319-x

  13. 13.

    Bowman, P., Hattersley, A. T., Knight, B. A., Broadbridge, E., Pettit, L., Reville, M., … Tonks, J. (2017 ). Neuropsychological impairments in children with KCNJ11 neonatal diabetes. Diabetic Medicine, 34(8), 1171–1173.

    Not in our library10.1111/dme.13375

  14. 14.
    Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study · 2018
    No notice
  15. 15.

    Busiah, K., Drunat, S., Vaivre‐Douret, L., Bonnefond, A., Simon, A., Flechtner, I., … Cavé, H. (2013 ). Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: A prospective cohort study [corrected]. The Lancet. Diabetes & Endocrinology, 1(3), 199–207.

    Not in our library10.1016/s2213-8587(13)70059-7

  16. 16.

    Carmody, D., Pastore, A. N., Landmeier, K. A., Letourneau, L. R., Martin, R., Hwang, J. L., … Greeley, S. A. W. (2016 ). Patients with KCNJ11‐related diabetes frequently have neuropsychological impairments compared with sibling controls. Diabetic Medicine, 33(10), 1380–1386.

    Not in our library10.1111/dme.13159

  17. 17.

    Codner, E., Flanagan, S., Ellard, S., Garcia, H., & Hattersley, A. T. (2005 ). High‐dose glibenclamide can replace insulin therapy despite transitory diarrhea in early‐onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care, 28(3), 758–759.

    Not in our library10.2337/diacare.28.3.758

  18. 18.

    Cook, D. L., & Hales, C. N. (1984 ). Intracellular ATP directly blocks K+ channels in pancreatic B‐cells. Nature, 311(5983), 271–273.

    Not in our library10.1038/311271a0

  19. 19.
    Clinical Diversity in Focal Congenital Hyperinsulinism in Infancy Correlates With Histological Heterogeneity of Islet Cell Lesions · 2018
    Not checked
  20. 20.

    Damaj, L., le Lorch, M., Verkarre, V., Werl, C., Hubert, L., Nihoul‐Fékété, C., … Jaubert, F. (2008 ). Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism. Journal of Clinical Endocrinology and Metabolism, 93(12), 4941–4947.

    Not in our library10.1210/jc.2008-0673

  21. 21.

    De Franco, E., Caswell, R., Houghton, J. A., Iotova, V., Hattersley, A. T., & Ellard, S. (2017 ). Analysis of cell‐free fetal DNA for non‐invasive prenatal diagnosis in a family with neonatal diabetes. Diabetic Medicine, 34(4), 582–585.

    Not in our library10.1111/dme.13180

  22. 22.
    The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study · 2015
    No notice
  23. 23.

    De Leon, D. D., Li, C., Delson, M. I., Matschinsky, F. M., Stanley, C. A., & Stoffers, D. A. (2008 ). Exendin‐(9‐39) corrects fasting hypoglycemia in SUR‐1‐/‐ mice by lowering cAMP in pancreatic beta‐cells and inhibiting insulin secretion. Journal of Biological Chemistry, 283(38), 25786–25793.

    Not in our library10.1074/jbc.m804372200

  24. 24.

    Demirbilek, H., Shah, P., Arya, V. B., Hinchey, L., Flanagan, S. E., Ellard, S., & Hussain, K. (2014 ). Long‐term follow‐up of children with congenital hyperinsulinism on octreotide therapy. Journal of Clinical Endocrinology and Metabolism, 99(10), 3660–3667.

    Not in our library10.1210/jc.2014-1866

  25. 25.

    Edghill, E. L., Gloyn, A. L., Goriely, A., Harries, L. W., Flanagan, S. E., Rankin, J., … Ellard, S. (2007 ). Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. Journal of Clinical Endocrinology and Metabolism, 92(5), 1773–1777.

    Not in our library10.1210/jc.2006-2817

  26. 26.

    Ellard, S., Flanagan, S. E., Girard, C. A., Patch, A. M., Harries, L. W., Parrish, A., … Ashcroft, F. M. (2007 ). Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. American Journal of Human Genetics, 81(2), 375–382.

    Not in our library10.1086/519174

  27. 27.

    Fendler, W., Pietrzak, I., Brereton, M. F., Lahmann, C., Gadzicki, M., Bienkiewicz, M., … Mlynarski, W. M. (2013 ). Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion. Diabetes Care, 36(8), 2311–2316.

    Not in our library10.2337/dc12-2166

  28. 28.

    Fernandez‐Marmiesse, A., Salas, A., Vega, A., Fernandez‐Lorenzo, J. R., Barreiro, J., & Carracedo, A. (2006 ). Mutation spectra of ABCC8 gene in Spanish patients with hyperinsulinism of infancy (HI). Human Mutation, 27(2), 214.

    Not in our library10.1002/humu.9401

  29. 29.

    Flanagan, S. E., Clauin, S., Bellanne‐Chantelot, C., de Lonlay, P., Harries, L. W., Gloyn, A. L., & Ellard, S. (2009 ). Update of mutations in the genes encoding the pancreatic beta‐cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Human Mutation, 30(2), 170–180.

    Not in our library10.1002/humu.20838

  30. 30.

    Flanagan, S. E., Dung, V. C., Houghton, J. A. L., De Franco, E., Ngoc, C. T. B., Damhuis, A., … Ellard, S. (2017 ). An ABCC8 nonsense mutation causing neonatal diabetes through altered transcript expression. Journal of Clinical Research in Pediatric Endocrinology, 9(3), 260–264.

    Not in our library10.4274/jcrpe.4624

  31. 31.

    Flanagan, S. E., Edghill, E. L., Gloyn, A. L., Ellard, S., & Hattersley, A. T. (2006 ). Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia, 49(6), 1190–1197.

    Not in our library10.1007/s00125-006-0246-z

  32. 32.

    Flanagan, S. E., Xie, W., Caswell, R., Damhuis, A., Vianey‐Saban, C., Akcay, T., … Ellard, S. (2013 ). Next‐generation sequencing reveals deep intronic cryptic ABCC8 and HADH splicing founder mutations causing hyperinsulinism by pseudoexon activation. American Journal of Human Genetics, 92(1), 131–136.

    Not in our library10.1016/j.ajhg.2012.11.017

  33. 33.

    Florez, J. C., Burtt, N., de Bakker, P. I. W., Almgren, P., Tuomi, T., Holmkvist, J., … Altshuler, D. (2004 ). Haplotype structure and genotype‐phenotype correlations of the sulfonylurea receptor and the islet ATP‐sensitive potassium channel gene region. Diabetes, 53(5), 1360–1368.

    Not in our library10.2337/diabetes.53.5.1360

  34. 34.

    Fokkema, I. F., Taschner, P. E., Schaafsma, G. C., Celli, J., Laros, J. F., & den Dunnen, J. T. (2011 ). LOVD v.2.0: The next generation in gene variant databases. Human Mutation, 32(5), 557–563.

    Not in our library10.1002/humu.21438

  35. 35.

    Glaser, B., Thornton, P., Otonkoski, T., & Junien, C. (2000 ). Genetics of neonatal hyperinsulinism. Archives of Disease in Childhood. Fetal and Neonatal Edition, 82(2), F79–F86.

    Not in our library10.1136/fn.82.2.f79

  36. 36.

    Gloyn, A. L., Cummings, E. A., Edghill, E. L., Harries, L. W., Scott, R., Costa, T., … Ellard, S. (2004 ). Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta‐cell potassium adenosine triphosphate channel. Journal of Clinical Endocrinology and Metabolism, 89(8), 3932–3935.

    Not in our library10.1210/jc.2004-0568

  37. 37.

    Gloyn, A. L., Diatloff‐Zito, C., Edghill, E. L., Bellanne‐Chantelot, C., Nivot, S., Coutant, R., … Robert, J. J. (2006a ). KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. European Journal of Human Genetics, 14(7), 824–830.

    Not in our library10.1038/sj.ejhg.5201629

  38. 38.

    Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., … Hattersley, A. T. (2004 ). Activating mutations in the gene encoding the ATP‐sensitive potassium‐channel subunit Kir6.2 and permanent neonatal diabetes. New England Journal of Medicine, 350(18), 1838–1849.

    Not in our library10.1056/nejmoa032922

  39. 39.

    Gloyn, A. L., Reimann, F., Girard, C., Edghill, E. L., Proks, P., Pearson, E. R., … Hattersley, A. T. (2005 ). Relapsing diabetes can result from moderately activating mutations in KCNJ11. Human Molecular Genetics, 14(7), 925–934.

    Not in our library10.1093/hmg/ddi086

  40. 40.

    Gloyn, A. L., Siddiqui, J., & Ellard, S. (2006 ). Mutations in the genes encoding the pancreatic beta‐cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Human Mutation, 27(3), 220–231.

    Not in our library10.1002/humu.20292

  41. 41.

    Gloyn, A. L., Weedon, M. N., Owen, K. R., Turner, M. J., Knight, B. A., Hitman, G., … Frayling, T. M. (2003 ). Large‐scale association studies of variants in genes encoding the pancreatic beta‐cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes, 52(2), 568–572.

    Not in our library10.2337/diabetes.52.2.568

  42. 42.

    Grulich‐Henn, J., Wagner, V., Thon, A., Schober, E., Marg, W., Kapellen, T. M., … Holl, R. W. (2010 ). Entities and frequency of neonatal diabetes: Data from the diabetes documentation and quality management system (DPV). Diabetic Medicine, 27(6), 709–712.

    Not in our library10.1111/j.1464-5491.2010.02965.x

  43. 43.

    Han, B., Mohamed, Z., Estebanez, M. S., Craigie, R. J., Newbould, M., Cheesman, E., … Dunne, M. J. (2017 ). Atypical forms of congenital hyperinsulinism in infancy are associated with mosaic patterns of immature islet cells. Journal of Clinical Endocrinology and Metabolism, 102(9), 3261–3267.

    Not in our library10.1210/jc.2017-00158

  44. 44.

    Hartemann‐Heurtier, A., Simon, A., Bellanne‐Chantelot, C., Reynaud, R., Cave, H., Polak, M., … Grimaldi, A. (2009 ). Mutations in the ABCC8 gene can cause autoantibody‐negative insulin‐dependent diabetes. Diabetes & Metabolism, 35(3), 233–235.

    Not in our library10.1016/j.diabet.2009.01.003

  45. 45.

    Hattersley, A. T., & Ashcroft, F. M. (2005 ). Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy. Diabetes, 54(9), 2503–2513.

    Not in our library10.2337/diabetes.54.9.2503

  46. 46.

    Helleskov, A., Melikyan, M., Globa, E., Shcherderkina, I., Poertner, F., Larsen, A. M., … Christesen, H. T. (2017 ). Both low blood glucose and insufficient treatment confer risk of neurodevelopmental impairment in congenital hyperinsulinism: A multinational cohort study. Frontiers in Endocrinology(Lausanne), 8, 156.

    Not in our library10.3389/fendo.2017.00156

  47. 47.

    Herrera, A., Vajravelu, M. E., Givler, S., Mitteer, L., Avitabile, C. M., Lord, K., & De Leon, D. D. (2018 ). Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. Journal of Clinical Endocrinology and Metabolism, 103(12), 4365–4372.

    Not in our library10.1210/jc.2018-01613

  48. 48.

    Houghton, J. A., Banerjee, I., Shaikh, G., Jabbar, S., Laver, T. W., Cheesman, E., … Dunne, M. J. (2019 ). Unravelling the genetic causes of mosaic islet morphology in congenital hyperinsulinism. The Journal of Pathology, 6(6), 12–16. https://www.diabetesgenes.org/

    Not in our library10.1002/cjp2.144

  49. 49.

    Hugill, A., Shimomura, K., Ashcroft, F. M., & Cox, R. D. (2010 ). A mutation in KCNJ11 causing human hyperinsulinism (Y12X) results in a glucose‐intolerant phenotype in the mouse. Diabetologia, 53(11), 2352–2356.

    Not in our library10.1007/s00125-010-1866-x

  50. 50.

    Huopio, H., Otonkoski, T., Vauhkonen, I., Reimann, F., Ashcroft, F. M., & Laakso, M. (2003 ). A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet, 361(9354), 301–307.

    Not in our library10.1016/s0140-6736(03)12325-2

  51. 51.

    Hussain, K., Flanagan, S. E., Smith, V. V., Ashworth, M., Day, M., Pierro, A., & Ellard, S. (2008 ). An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes, 57(1), 259–263.

    Not in our library10.2337/db07-0998

  52. 52.

    Ismail, D., Kapoor, R. R., Smith, V. V., Ashworth, M., Blankenstein, O., Pierro, A., … Hussain, K. (2012 ). The heterogeneity of focal forms of congenital hyperinsulinism. Journal of Clinical Endocrinology and Metabolism, 97(1), E94–E99.

    Not in our library10.1210/jc.2011-1628

  53. 53.

    Jack, M. M., Walker, R. M., Thomsett, M. J., Cotterill, A. M., & Bell, J. R. (2000 ). Histologic findings in persistent hyperinsulinemic hypoglycemia of infancy: Australian experience. Pediatric and Developmental Pathology, 3(6), 532–547.

    Not in our library10.1007/s100240010117

  54. 54.

    Kapoor, R. R., Flanagan, S. E., Arya, V. B., Shield, J. P., Ellard, S., & Hussain, K. (2013 ). Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. European Journal of Endocrinology, 168(4), 557–564.

    Not in our library10.1530/eje-12-0673

  55. 55.

    Karschin, C., Ecke, C., Ashcroft, F. M., & Karschin, A. (1997 ). Overlapping distribution of K(ATP) channel‐forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. FEBS Letters, 401(1), 59–64.

    Not in our library10.1016/s0014-5793(96)01438-x

  56. 56.

    Koster, J. C., Marshall, B. A., Ensor, N., Corbett, J. A., & Nichols, C. G. (2000 ). Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell, 100(6), 645–654.

    Not in our library10.1016/s0092-8674(00)80701-1

  57. 57.

    Koufakis, T., Sertedaki, A., Tatsi, E. B., Trakatelli, C. M., Karras, S. N., Manthou, E., … Kotsa, K. (2019 ). First Report of Diabetes Phenotype due to a Loss‐of‐Function ABCC8 Mutation Previously Known to Cause Congenital Hyperinsulinism. Case Reports in Genetics, 2019, 3654618–5.

    Not in our library10.1155/2019/3654618

  58. 58.

    Kumaraguru, J., Flanagan, S. E., Greeley, S. A., Nuboer, R., Stoy, J., Philipson, L. H., … Rubio‐Cabezas, O. (2009 ). Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: A previously unreported side effect. Diabetes Care, 32(8), 1428–1430.

    Not in our library10.2337/dc09-0280

  59. 59.

    Landmeier, K. A., Lanning, M., Carmody, D., Greeley, S. A. W., & Msall, M. E. (2017 ). ADHD, learning difficulties and sleep disturbances associated with KCNJ11‐related neonatal diabetes. Pediatric Diabetes, 18(7), 518–523.

    Not in our library10.1111/pedi.12428

  60. 60.

    Lanning, M. S., Carmody, D., Szczerbinski, L., Letourneau, L. R., Naylor, R. N., & Greeley, S. A. W. (2018 ). Hypoglycemia in sulfonylurea‐treated KCNJ11‐neonatal diabetes: Mild‐moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures. Pediatric Diabetes, 19(3), 393–397.

    Not in our library10.1111/pedi.12599

  61. 61.
    Analysis of protein-coding genetic variation in 60,706 humans · 2016
    No notice
  62. 62.

    Liss, B., Bruns, R., & Roeper, J. (1999 ). Alternative sulfonylurea receptor expression defines metabolic sensitivity of K‐ATP channels in dopaminergic midbrain neurons. EMBO Journal, 18(4), 833–846.

    Not in our library10.1093/emboj/18.4.833

  63. 63.

    de Lonlay, P., Fournet, J. C., Rahier, J., Gross‐Morand, M. S., Poggi‐Travert, F., Foussier, V., … Junien, C. (1997 ). Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. Journal of Clinical Investigation, 100(4), 802–807.

    Not in our library10.1172/jci119594

  64. 64.

    de Lonlay, P., Fournet, J. C., Touati, G., Groos, M. S., Martin, D., Sevin, C., … Robert, J. J. (2002 ). Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. European Journal of Pediatrics, 161(1), 37–48.

    Not in our library10.1007/s004310100847

  65. 65.

    Massa, O., Iafusco, D., D'Amato, E., Gloyn, A. L., Hattersley, A. T., Pasquino, B., … Barbetti, F. (2005 ). KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Human Mutation, 25(1), 22–27.

    Not in our library10.1002/humu.20124

  66. 66.

    Mathew, P. M., Young, J. M., Abu‐Osba, Y. K., Mulhern, B. D., Hammoudi, S., Hamdan, J. A., & Sa'di, A. R. (1988 ). Persistent neonatal hyperinsulinism. Clinical Pediatrics (Cleveland, OH), 27(3), 148–151.

    Not in our library10.1177/000992288802700307

  67. 67.

    Miki, T., Nagashima, K., Tashiro, F., Kotake, K., Yoshitomi, H., Tamamoto, A., … Seino, S. (1998 ). Defective insulin secretion and enhanced insulin action in KATP channel‐deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 95(18), 10402–10406.

    Not in our library10.1073/pnas.95.18.10402

  68. 68.

    Mohnike, K., Wieland, I., Barthlen, W., Vogelgesang, S., Empting, S., Mohnike, W., … Zenker, M. (2014 ). Clinical and genetic evaluation of patients with KATP channel mutations from the German registry for congenital hyperinsulinism. Hormone research in pædiatrics, 81(3), 156–168.

    Not in our library10.1159/000356905

  69. 69.

    Myngheer, N., Allegaert, K., Hattersley, A., McDonald, T., Kramer, H., Ashcroft, F. M., … Casteels, K. (2014 ). Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11‐related neonatal diabetes. Diabetes Care, 37(12), 3333–3335.

    Not in our library10.2337/dc14-1247

  70. 70.

    Nestorowicz, A. (1996 ). Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Human Molecular Genetics, 5(11), 1813–1822.

    Not in our library10.1093/hmg/5.11.1813

  71. 71.

    Ng, C. M., Tang, F., Seeholzer, S. H., Zou, Y., & De Leon, D. D. (2018 ). Population pharmacokinetics of exendin‐(9‐39) and clinical dose selection in patients with congenital hyperinsulinism. British Journal of Clinical Pharmacology, 84(3), 520–532.

    Not in our library10.1111/bcp.13463

  72. 72.

    Nichols, C. G., Shyng, S. L., Nestorowicz, A., Glaser, B., Clement, J. Pt, Gonzalez, G., … Bryan, J. (1996 ). Adenosine diphosphate as an intracellular regulator of insulin secretion. Science, 272(5269), 1785–1787.

    Not in our library10.1126/science.272.5269.1785

  73. 73.

    Nielsen, E. M., Hansen, L., Carstensen, B., Echwald, S. M., Drivsholm, T., Glumer, C., … Pedersen, O. (2003 ). The E23K variant of Kir6.2 associates with impaired post‐OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes, 52(2), 573–577.

    Not in our library10.2337/diabetes.52.2.573

  74. 74.

    Otonkoski, T., Ammala, C., Huopio, H., Cote, G. J., Chapman, J., Cosgrove, K., … Thomas, P. M. (1999 ). A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes, 48(2), 408–415.

    Not in our library10.2337/diabetes.48.2.408

  75. 75.

    Otonkoski, T., Nanto‐Salonen, K., Seppanen, M., Veijola, R., Huopio, H., Hussain, K., … Minn, H. (2006 ). Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]‐DOPA positron emission tomography. Diabetes, 55(1), 13–18.

    Not in our library

  76. 76.

    Patch, A. M., Flanagan, S. E., Boustred, C., Hattersley, A. T., & Ellard, S. (2007 ). Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes, obesity & metabolism, 9(Suppl 2), 28–39.

    Not in our library10.1111/j.1463-1326.2007.00772.x

  77. 77.

    Patel, P., Charles, L., Corbin, J., Goldfine, I. D., Johnson, K., Rubin, P., & De Leon, D. D. (2018 ). A unique allosteric insulin receptor monoclonal antibody that prevents hypoglycemia in the SUR‐1(‐/‐) mouse model of KATP hyperinsulinism. mAbs, 10(5), 796–802.

    Not in our library10.1080/19420862.2018.1457599

  78. 78.

    Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., … Hattersley, A. T. (2006 ). Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. New England Journal of Medicine, 355(5), 467–477.

    Not in our library10.1056/nejmoa061759

  79. 79.

    Pinney, S. E., Ganapathy, K., Bradfield, J., Stokes, D., Sasson, A., Mackiewicz, K., … Stanley, C. A. (2013 ). Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Hormone Research in Paediatrics, 80(1), 18–27.

    Not in our library10.1159/000351943

  80. 80.

    Powell, P. D., Bellanne‐Chantelot, C., Flanagan, S. E., Ellard, S., Rooman, R., Hussain, K., … Cosgrove, K. E. (2011 ). In vitro recovery of ATP‐sensitive potassium channels in {beta}‐cells from patients with congenital hyperinsulinism of infancy. Diabetes, 60(4), 1223–1228.

    Not in our library10.2337/db10-1443

  81. 81.

    Proks, P., Arnold, A. L., Bruining, J., Girard, C., Flanagan, S. E., Larkin, B., … Ellard, S. (2006 ). A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Human Molecular Genetics, 15(11), 1793–1800.

    Not in our library10.1093/hmg/ddl101

  82. 82.

    Rafiq, M., Flanagan, S. E., Patch, A. M., Shields, B. M., Ellard, S., & Hattersley, A. T. (2008 ). Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care, 31(2), 204–209.

    Not in our library10.2337/dc07-1785

  83. 83.

    Rahier, J., Falt, K., Muntefering, H., Becker, K., Gepts, W., & Falkmer, S. (1984 ). The basic structural lesion of persistent neonatal hypoglycaemia with hyperinsulinism: Deficiency of pancreatic D cells or hyperactivity of B cells? Diabetologia, 26(4), 282–289.

    Not in our library10.1007/bf00283651

  84. 84.

    Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier‐Foster, J., … Rehm, H. L. (2015 ). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424.

    Not in our library10.1038/gim.2015.30

  85. 85.

    Rorsman, P., & Trube, G. (1985 ). Glucose dependent K + ‐channels in pancreatic beta‐cells are regulated by intracellular ATP. Pflügers Archiv: European Journal of Physiology, 405(4), 305–309.

    Not in our library10.1007/bf00595682

  86. 86.

    Sagen, J. V., Raeder, H., Hathout, E., Shehadeh, N., Gudmundsson, K., Baevre, H., … Njolstad, P. R. (2004 ). Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes, 53(10), 2713–2718.

    Not in our library10.2337/diabetes.53.10.2713

  87. 87.

    Sakura, H., Ammala, C., Smith, P. A., Gribble, F. M., & Ashcroft, F. M. (1995 ). Cloning and functional expression of the cDNA encoding a novel ATP‐sensitive potassium channel subunit expressed in pancreatic beta‐cells, brain, heart and skeletal muscle. FEBS Letters, 377(3), 338–344.

    Not in our library10.1016/0014-5793(95)01369-5

  88. 88.

    Schmahmann, J. D., & Sherman, J. C. (1998 ). The cerebellar cognitive affective syndrome. Brain, 121(Pt 4), 561–579.

    Not in our library10.1093/brain/121.4.561

  89. 89.

    Seghers, V., Nakazaki, M., DeMayo, F., Aguilar‐Bryan, L., & Bryan, J. (2000 ). Sur1 knockout mice. A model for K(ATP) channel‐independent regulation of insulin secretion. Journal of Biological Chemistry, 275(13), 9270–9277.

    Not in our library10.1074/jbc.275.13.9270

  90. 90.

    Sempoux, C., Capito, C., Bellanne‐Chantelot, C., Verkarre, V., de Lonlay, P., Aigrain, Y., … Rahier, J. (2011 ). Morphological mosaicism of the pancreatic islets: A novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. Journal of Clinical Endocrinology and Metabolism, 96(12), 3785–3793.

    Not in our library10.1210/jc.2010-3032

  91. 91.

    Senniappan, S., Alexandrescu, S., Tatevian, N., Shah, P., Arya, V., Flanagan, S., … Hussain, K. (2014 ). Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. New England Journal of Medicine, 370(12), 1131–1137.

    Not in our library10.1056/nejmoa1310967

  92. 92.

    Shah, R. P., Spruyt, K., Kragie, B. C., Greeley, S. A., & Msall, M. E. (2012 ). Visuomotor performance in KCNJ11‐related neonatal diabetes is impaired in children with DEND‐associated mutations and may be improved by early treatment with sulfonylureas. Diabetes Care, 35(10), 2086–2088.

    Not in our library10.2337/dc11-2225

  93. 93.

    Shepherd, M., Brook, A. J., Chakera, A. J., & Hattersley, A. T. (2017 ). Management of sulfonylurea‐treated monogenic diabetes in pregnancy: Implications of placental glibenclamide transfer. Diabetic Medicine, 34(10), 1332–1339.

    Not in our library10.1111/dme.13388

  94. 94.

    Shepherd, M., Shields, B., Hammersley, S., Hudson, M., McDonald, T. J., Colclough, K., … Hattersley, A. T. (2016 ). Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care, 39(11), 1879–1888.

    Not in our library10.2337/dc16-0645

  95. 95.

    Shields, B. M., Shepherd, M., Hudson, M., McDonald, T. J., Colclough, K., Peters, J., … Hattersley, A. T. (2017 ). Population‐based assessment of a biomarker‐based screening pathway to aid diagnosis of monogenic diabetes in young‐onset patients. Diabetes Care, 40(8), 1017–1025.

    Not in our library10.2337/dc17-0224

  96. 96.

    Shimomura, K., Tusa, M., Iberl, M., Brereton, M. F., Kaizik, S., Proks, P., … Ashcroft, F. M. (2013 ). A mouse model of human hyperinsulinism produced by the E1506K mutation in the sulphonylurea receptor SUR1. Diabetes, 62(11), 3797–3806.

    Not in our library10.2337/db12-1611

  97. 97.

    Snider, K. E., Becker, S., Boyajian, L., Shyng, S. L., MacMullen, C., Hughes, N., … Ganguly, A. (2013 ). Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. Journal of Clinical Endocrinology and Metabolism, 98(2), E355–E363.

    Not in our library10.1210/jc.2012-2169

  98. 98.

    Stoy, J., Greeley, S. A., Paz, V. P., Ye, H., Pastore, A. N., Skowron, K. B., … Philipson, L. H. (2008 ). Diagnosis and treatment of neonatal diabetes: A United States experience. Pediatric Diabetes, 9(5), 450–459.

    Not in our library10.1111/j.1399-5448.2008.00433.x

  99. 99.

    Tarasov, A. I., Nicolson, T. J., Riveline, J. P., Taneja, T. K., Baldwin, S. A., Baldwin, J. M., … Rutter, G. A. (2008 ). A rare mutation in ABCC8/SUR1 leading to altered ATP‐sensitive K + channel activity and beta‐cell glucose sensing is associated with type 2 diabetes in adults. Diabetes, 57(6), 1595–1604.

    Not in our library10.2337/db07-1547

  100. 100.

    Taschenberger, G., Mougey, A., Shen, S., Lester, L. B., LaFranchi, S., & Shyng, S. L. (2002 ). Identification of a familial hyperinsulinism‐causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels. Journal of Biological Chemistry, 277(19), 17139–17146.

    Not in our library10.1074/jbc.m200363200

  101. 101.

    Thomas, P., Ye, Y., & Lightner, E. (1996 ). Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Human Molecular Genetics, 5(11), 1809–1812.

    Not in our library10.1093/hmg/5.11.1809

  102. 102.

    Thomas, P. M., Cote, G. J., Wohllk, N., Haddad, B., Mathew, P. M., Rabl, W., … Bryan, J. (1995 ). Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science, 268(5209), 426–429.

    Not in our library10.1126/science.7716548

  103. 103.

    Thornton, P. S., Stanley, C. A., De Leon, D. D., Harris, D., Haymond, M. W., Hussain, K., … Wolfsdorf, J. I. (2015 ). Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. Journal of Pediatrics, 167(2), 238–245.

    Not in our library10.1016/j.jpeds.2015.03.057

  104. 104.

    Thurber, B. W., Carmody, D., Tadie, E. C., Pastore, A. N., Dickens, J. T., Wroblewski, K. E., … Greeley, S. A., United States Neonatal Diabetes Working G. (2015 ). Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11‐related neonatal diabetes. Diabetologia, 58(7), 1430–1435.

    Not in our library10.1007/s00125-015-3593-9

  105. 105.

    Tornovsky, S., Crane, A., Cosgrove, K. E., Hussain, K., Lavie, J., Heyman, M., … Glaser, B. (2004 ). Hyperinsulinism of infancy: Novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity. Journal of Clinical Endocrinology and Metabolism, 89(12), 6224–6234.

    Not in our library10.1210/jc.2004-1233

  106. 106.

    Wiedemann, B., Schober, E., Waldhoer, T., Koehle, J., Flanagan, S. E., Mackay, D. J., … Hofer, S. (2010 ). Incidence of neonatal diabetes in Austria‐calculation based on the Austrian Diabetes Register. Pediatric Diabetes, 11(1), 18–23.

    Not in our library10.1111/j.1399-5448.2009.00530.x

  107. 107.

    Zung, A., Glaser, B., Nimri, R., & Zadik, Z. (2004 ). Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. Journal of Clinical Endocrinology and Metabolism, 89(11), 5504–5507.

    Not in our library10.1210/jc.2004-1241

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.